SEAS remain rough for Vytorin
This article was originally published in Scrip
Pressure onMerck/Schering-PloughPharmaceuticals Vytorin (ezetimibe plus simvastatin) is set to continue after the SEAS study showed that the combination hypolipaemic product failed to reach its primary endpoint in a new indication of aortic stenosis, and was associated with an increased risk of developing cancer.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.